Protalix BioTherapeutics
PLX
100 hedge funds and large institutions have $36.6M invested in Protalix BioTherapeutics in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 9 closing their positions.
200% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 9
70% more call options, than puts
Call options by funds: $651K | Put options by funds: $383K
40% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 20
36% more capital invested
Capital invested by funds: $26.8M → $36.6M (+$9.74M)
20% more funds holding
Funds holding: 83 → 100 (+17)
2.4% more ownership
Funds ownership: 18.53% → 20.93% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCO
MAK Capital One
New York
|
+$8.79M |
| 2 |
PFS
Prospera Financial Services
Dallas,
Texas
|
+$1.04M |
| 3 |
State Street
Boston,
Massachusetts
|
+$962K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$665K |
| 5 |
Morgan Stanley
New York
|
+$421K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.31M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$788K |
| 3 |
Jane Street
New York
|
-$676K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$378K |
| 5 |
Barclays
London,
United Kingdom
|
-$243K |
PLX Hedge Fund Activity: Q1 2026 in Review
100 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2026, worth a combined $36.6M — up 36% from $26.8M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PLX positions and 9 closed out — a net gain of 18 holders — while 28 added to existing stakes and 20 trimmed.
The largest buyer was MAK Capital One, opening a new position worth an estimated $8.79M. The largest seller was Opaleye Management, cutting an estimated $5.31M.
- 100 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2026, up from 83 in Q4 2025.
- Funds reported $36.6M of Protalix BioTherapeutics stock for Q1 2026, up 36% quarter-over-quarter.
- 27 funds opened new Protalix BioTherapeutics positions in Q1 2026 and 9 closed out, a net change of +18 holders.
- The largest Protalix BioTherapeutics buyer in Q1 2026 was MAK Capital One, an estimated $8.79M added.
- The largest Protalix BioTherapeutics seller in Q1 2026 was Opaleye Management, an estimated $5.31M sold.
Based on aggregated 13F filings for Q1 2026.